

**Listing of Claims:**

1-24. (canceled)

25. (previously presented) A pharmaceutical composition for activation of immune system cells against HIV, the composition comprising HIV infected cells that have been treated with hyaluronidase.

26. (previously presented) The pharmaceutical composition of claim 25 wherein the HIV infected cells are human host cells.

27. (previously presented) The pharmaceutical composition of claim 26 wherein the human host cells are Peripheral Blood Mononuclear Cells.

28. (previously presented) The pharmaceutical composition of claim 25 wherein the hyaluronidase treated HIV infected cells form HIV immunogens.

29. (previously presented) The pharmaceutical composition of claim 28 wherein the HIV immunogens prime and activate Antigen Presenting Cells inducing expansion of immune response to naïve cells that are made resistant to HIV challenge.

30. (previously presented) The pharmaceutical composition of claim 29 wherein the Antigen Presenting Cells are macrophages, monocytes or both.

31-32. (canceled)

33. (new) A composition comprising HIV infected cells that have been treated with hyaluronidase, and a pharmaceutically acceptable carrier or diluent.

34. (new) The composition of claim 33 wherein the HIV infected cells are human host cells.

35. (new) The composition of claim 34 wherein the human host cells are Peripheral Blood Mononuclear Cells.

36. (new) The composition of claim 33 wherein the hyaluronidase treated HIV infected cells form HIV immunogens or antigens.

37. (new) The composition of claim 36 wherein the HIV immunogens prime and activate Antigen Presenting Cells inducing expansion of immune response to naïve cells that are made resistant to HIV challenge.

38. (new) The composition of claim 37 wherein the Antigen Presenting Cells are macrophages, monocytes or both.